TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+1.3%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.45B
AUM Growth
+$2.45B
(-0.48%)
Cap. Flow
-$12.8M
Cap. Flow
% of AUM
-0.52%
Top 10 Holdings %
Top 10 Hldgs %
40.31%
Holding
207
New
13
Increased
46
Reduced
57
Closed
10
Top Buys
| 1 |
Vertex Pharmaceuticals
VRTX
|
$8.44M |
| 2 |
Intuitive Surgical
ISRG
|
$8.07M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$7.96M |
| 4 |
Boston Scientific
BSX
|
$6.82M |
| 5 |
Gilead Sciences
GILD
|
$5.86M |
Top Sells
| 1 |
Biogen
BIIB
|
$21M |
| 2 |
Illumina
ILMN
|
$14.4M |
| 3 |
Elevance Health
ELV
|
$10.7M |
| 4 |
AGN
Allergan plc
AGN
|
$8.2M |
| 5 |
Welltower
WELL
|
$6.93M |
Sector Composition
| 1 | Healthcare | 95.11% |
| 2 | Real Estate | 2.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $136M | 5.56% | 1,473,710 | – | – |
|
2
Amgen
AMGN
$155B
| $134M | 5.49% | 729,658 +25,275 | +4% | +$4.66M |
|
|
3
Gilead Sciences
GILD
$140B
| $124M | 5.06% | 1,836,112 +86,724 | +5% | +$5.86M |
|
4
Johnson & Johnson
JNJ
$427B
| $124M | 5.06% | 890,004 -7,986 | -0.9% | -$1.11M |
|
|
5
Vertex Pharmaceuticals
VRTX
$100B
| $89.8M | 3.66% | 489,734 +46,022 | +10% | +$8.44M |
|
6
Pfizer
PFE
$141B
| $89.6M | 3.66% | 2,068,265 -2,500 | -0.1% | -$108K |
|
7
Merck
MRK
$210B
| $85M | 3.47% | 1,013,695 +20,612 | +2% | +$1.73M |
|
8
UnitedHealth
UNH
$281B
| $79.1M | 3.23% | 324,133 | – | – |
|
|
9
Illumina
ILMN
$15.8B
| $73.1M | 2.98% | 198,471 -39,043 | -16% | -$14.4M |
|
|
10
Biogen
BIIB
$19.4B
| $52.5M | 2.14% | 224,690 -89,588 | -29% | -$21M |
|
|
ALXN
11
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $52.4M | 2.14% | 400,014 +24,309 | +6% | +$3.18M |
|
|
12
Regeneron Pharmaceuticals
REGN
$61.5B
| $52.3M | 2.13% | 166,968 +25,436 | +18% | +$7.96M |
|
13
Medtronic
MDT
$119B
| $46.8M | 1.91% | 480,035 -11,967 | -2% | -$1.17M |
|
14
Incyte
INCY
$16.5B
| $43.4M | 1.77% | 510,933 -18,200 | -3% | -$1.55M |
|
15
Abbott
ABT
$231B
| $42.4M | 1.73% | 504,148 +47,100 | +10% | +$3.96M |
|
16
Thermo Fisher Scientific
TMO
$186B
| $40M | 1.63% | 136,198 -6,545 | -5% | -$1.92M |
|
17
Bristol-Myers Squibb
BMY
$96B
| $33.5M | 1.37% | 738,044 | – | – |
|
18
CVS Health
CVS
$92.8B
| $31.4M | 1.28% | 575,401 +69,037 | +14% | +$3.76M |
|
|
19
Intuitive Surgical
ISRG
$170B
| $29.2M | 1.19% | 55,675 +15,394 | +38% | +$8.07M |
|
|
20
Elevance Health
ELV
$71.8B
| $29.2M | 1.19% | 103,456 -37,902 | -27% | -$10.7M |
|
21
Zoetis
ZTS
$69.3B
| $28.2M | 1.15% | 248,584 -8,417 | -3% | -$955K |
|
22
Eli Lilly
LLY
$657B
| $28.1M | 1.14% | 253,199 -42,121 | -14% | -$4.67M |
|
|
23
Boston Scientific
BSX
$156B
| $27.2M | 1.11% | 632,250 +158,631 | +33% | +$6.82M |
|
24
Novartis
NVS
$245B
| $25.3M | 1.03% | 277,047 +200 | +0.1% | +$18.3K |
|
25
AbbVie
ABBV
$372B
| $24.2M | 0.99% | 333,316 +13,103 | +4% | +$953K |
|